Methods
Data were extracted for all children with JIA who were enrolled up to December 28, 2010. Children who had ever received biologic DMARDs were compared to children who had not using relative risks (RR) and unpaired t-tests.
Results 1072 children with JIA were enrolled during the first 7 months by 26 centers. The categorical characteristics of the cohort are shown in Table 1 and the continuous characteristics of the cohort are shown in Table 2 . 77% had received at least one non-biologic DMARD at enrollment, most commonly methotrexate. 69% had received corticosteroids during their disease course, most frequently intra-articular (49%) and daily oral (36%). 45% of the cohort received one or more biologic DMARD during their disease course. The proportion of patients who received specific biologic agents is shown in Table 3 .
Children receiving biologic DMARDs were older at enrollment (mean age 13 years versus 10 years; p <0.001) and had a longer disease duration (mean 6 years versus 4 years; p<0.001). Children with imaging evidence of joint damage (RR 1.6; 95% CI: 1.3-1.9), positive RF (RR: 1.36; 95% CI 1.1 -1.6), or positive anti-CCP (RR: 1.35; 1.1-1.7) were more likely to have received a biologic DMARD. Children with oligoarthritis were less likely to have received a biologic DMARD than other categories.
Conclusion
The majority of patients with JIA enrolled into the CAR-RAnet registry has relatively low disease activity, minimal disability, and have received at least one DMARD. Positive anti-CCP or RF, joint damage on imaging, older age at enrollment and longer disease duration were associated with biologic DMARD use. Limitations include the underrepresentation of non-English speaking families and enrollment bias. Continued enrollment into this cohort will support future analyses with increased sample sizes and the potential for longitudinal data analysis. Table 3 Biologic medication Current use Prior use N (% of biologic users) N (% of biologic users)
TNF-alpha inhibitirs
Adalimumab 78 (7) 70 (6) Cartolizumab 4 (<1) 0 Etanercept 214 (20) 183 (17) Gollimumab 5 (<1) 4 (<1)
Inflximab 46 (4) 46 (4)
IL-1 Inhibitors
Ankira 14 (1) 22 (2) Rilonacept 2 (<1) 2 (<1)
Other biologic agents
Abatacept 24 (2) 8 (<1) Rituximab 2 (<1) 8 (<1) Tocilizumab 6 (<1) 0 (<1)
